Literature DB >> 27446342

Immunomodulatory effects of therapeutic plasma exchange on monocytes in antiphospholipid syndrome.

Anush Martirosyan1, Martin Petrek2, Amit Kishore2, Gayane Manukyan1.   

Abstract

Antiphospholipid syndrome (APS) is a systemic autoimmune disorder characterized by thrombosis and recurrent fetal loss, with the persistent presence of antiphospholipid antibodies (aPLs). aPLs exert their pathogenic effect via the overproduction of tissue factor and activation of complement and several cell types, including endothelial cells, platelets and notably monocytes. As a result, a hypercoagulable state develops leading to APS-associated obstetric complications and fetal loss. Despite being far from optimal, treatment of APS usually includes heparin and low dose aspirin. Recently, plasma exchange (PE) therapy was successfully used in patients with APS with obstetric complications who did not respond to the standard treatment. Therefore, the present study investigated the mechanism underlying PE action, and aimed to determine whether PE affects the functional activity of APS monocytes by examining the expression of 11 mRNA transcripts encoding cytokines, signaling molecules and transcription factors. Monocytes were collected prior to and following the PE treatment from women with APS who experienced recurrent pregnancy losses, as well as from healthy volunteers. Compared with control cells, APS monocytes showed deregulated expression of interleukin (IL)-1β, IL-6, IL-23, chemokine (C-C motif) ligand 2 (CCL2), C-X-C motif chemokine 10 (CXCL10), toll-like receptor 2, and signal transducer and activator of transcription 3. PE treatment resulted in increased IL-1β, IL-6, IL-23, CCL2, P2X7 and tumor necrosis factor-α mRNA transcripts in APS monocytes, restoring the mRNA expression levels to within normal ranges. Furthermore, PE therapy counterbalanced the expression levels of CCL2 and CXCL10, the levels of which are indicative of T helper cell 1/2 balance. The results of the present study indicate that the altered transcriptional profile in APS monocytes was restored by the immunomodulatory effect of plasmapheresis.

Entities:  

Keywords:  antiphospholipid syndrome; cytokines; mRNA; monocytes; therapeutic plasma exchange

Year:  2016        PMID: 27446342      PMCID: PMC4950391          DOI: 10.3892/etm.2016.3441

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  45 in total

1.  Plasma exchange and immunoadsorption effectively remove antiphospholipid antibodies in pregnant patients with antiphospholipid syndrome.

Authors:  Agnese Bontadi; Amelia Ruffatti; Piero Marson; Tiziana Tison; Marta Tonello; Ariela Hoxha; Giustina De Silvestro; Leonardo Punzi
Journal:  J Clin Apher       Date:  2012-04-24       Impact factor: 2.821

2.  Plasmapheresis affects T helper type-1/T helper type-2 balance of circulating peripheral lymphocytes.

Authors:  H Goto; H Matsuo; S Nakane; H Izumoto; T Fukudome; C Kambara; N Shibuya
Journal:  Ther Apher       Date:  2001-12

3.  Understanding the plasmapheresis donor in a voluntary, nonremunerated environment.

Authors:  Liliana L Bove; Tim Bednall; Barbara Masser; Mark Buzza
Journal:  Transfusion       Date:  2011-05-12       Impact factor: 3.157

4.  Cytokine production by maternal lymphocytes during normal human pregnancy and in unexplained recurrent spontaneous abortion.

Authors:  R Raghupathy; M Makhseed; F Azizieh; A Omu; M Gupta; R Farhat
Journal:  Hum Reprod       Date:  2000-03       Impact factor: 6.918

5.  Hughes syndrome: antiphospholipid antibodies move closer to thrombosis in 1994.

Authors:  M A Khamashta; R A Asherson
Journal:  Br J Rheumatol       Date:  1995-06

Review 6.  Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a TH2 phenomenon?

Authors:  T G Wegmann; H Lin; L Guilbert; T R Mosmann
Journal:  Immunol Today       Date:  1993-07

7.  Case reports of the use of immunoadsorption or plasma exchange in high-risk pregnancies of women with antiphospholipid syndrome.

Authors:  Maria Bortolati; Piero Marson; Silvia Chiarelli; Tiziana Tison; Myriam Facchinetti; Maria Teresa Gervasi; Giustina De Silvestro; Amelia Ruffatti
Journal:  Ther Apher Dial       Date:  2009-04       Impact factor: 1.762

8.  Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study.

Authors:  Monica Galli; Giovanna Borrelli; Eva Marie Jacobsen; Rosa Maria Marfisi; Guido Finazzi; Roberto Marchioli; Finn Wisloff; Stefana Marziali; Olivier Morboeuf; Tiziano Barbui
Journal:  Blood       Date:  2007-04-17       Impact factor: 22.113

9.  Proteomic analysis in monocytes of antiphospholipid syndrome patients: deregulation of proteins related to the development of thrombosis.

Authors:  Chary López-Pedrera; Maria José Cuadrado; Vanessa Herández; Paula Buendïa; Maria Angeles Aguirre; Nuria Barbarroja; Luis Arïstides Torres; José Manuel Villalba; Francisco Velasco; Munther Khamashta
Journal:  Arthritis Rheum       Date:  2008-09

10.  Venous thrombosis-associated inflammation and attenuation with neutralizing antibodies to cytokines and adhesion molecules.

Authors:  T W Wakefield; R M Strieter; C A Wilke; A M Kadell; S K Wrobleski; M D Burdick; R Schmidt; S L Kunkel; L J Greenfield
Journal:  Arterioscler Thromb Vasc Biol       Date:  1995-02       Impact factor: 8.311

View more
  4 in total

Review 1.  Environmental Triggers of Autoreactive Responses: Induction of Antiphospholipid Antibody Formation.

Authors:  Anush Martirosyan; Rustam Aminov; Gayane Manukyan
Journal:  Front Immunol       Date:  2019-07-10       Impact factor: 7.561

2.  Anti-domain 1 β2 glycoprotein antibodies increase expression of tissue factor on monocytes and activate NK Cells and CD8+ cells in vitro.

Authors:  Gayane Manukyan; Anush Martirosyan; Ludek Slavik; Sona Margaryan; Jana Ulehlova; Zuzana Mikulkova; Antonin Hlusi; Tomas Papajik; Eva Kriegova
Journal:  Auto Immun Highlights       Date:  2020-03-02

3.  Evaluation of membrane-based therapeutic plasma exchange as adjunctive treatment for immune-mediated hematologic disorders in dogs.

Authors:  Thierry Francey; Mathieu Etter; Ariane Schweighauser
Journal:  J Vet Intern Med       Date:  2021-02-11       Impact factor: 3.333

4.  Thrombocytopenia in a cohort of primary and secondary antiphospholipid syndrome patients: Relation to clinical, laboratory manifestations and damage index.

Authors:  Sherif Gamal; Samar Mohamed; Abdelkawy Moghazy
Journal:  Arch Rheumatol       Date:  2022-01-23       Impact factor: 1.007

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.